Literature DB >> 9116230

Working memory failure by stimulation of hippocampal adenosine A1 receptors in rats.

M Ohno1, S Watanabe.   

Abstract

THE highly selective adenosine A1 receptor agonist N6-cyclohexyladenosine (CHA) significantly increased the number of errors (attempts to pass through two incorrect panels of the three panel-gates at four choice points) in the working memory task with a three-panel runway setup, when injected bilaterally at 0.3 and 1.0 microgram per side into the dorsal hippocampus. Pretreatment with the selective adenosine A1 receptor antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX; 1 mg kg-1, i.p.) prevented the increase in working memory errors induced by intrahippocampal administration of CHA (1.0 microgram per side). CGS-21680, a highly selective agonist for adenosine A2 receptors, had no effect on the number of working memory errors, when administered intrahippocampally at a dose of 1.0 microgram per side. These results suggest that activation of hippocampal adenosine A1 receptors interferes with neural processes involved in working memory function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9116230     DOI: 10.1097/00001756-199611250-00043

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  12 in total

1.  Regulation of hippocampal cannabinoid CB1 receptor actions by adenosine A1 receptors and chronic caffeine administration: implications for the effects of Δ9-tetrahydrocannabinol on spatial memory.

Authors:  Vasco C Sousa; Natália Assaife-Lopes; Joaquim A Ribeiro; Judith A Pratt; Ros R Brett; Ana M Sebastião
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

2.  Neuromodulatory effect of propentofylline on rat brain under acute and long-term hypoperfusion.

Authors:  K Plaschke; M Grant; M A Weigand; J Züchner; E Martin; H J Bardenheuer
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 3.  Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy.

Authors:  Detlev Boison; Philipp Singer; Hai-Ying Shen; Joram Feldon; Benjamin K Yee
Journal:  Neuropharmacology       Date:  2011-02-17       Impact factor: 5.250

4.  Adenosine A1 Receptors Play an Important Protective Role Against Cognitive Impairment and Long-Term Potentiation Inhibition in a Pentylenetetrazol Mouse Model of Epilepsy.

Authors:  Qing Zhou; Suiqiang Zhu; Yuchen Guo; Lifei Lian; Qi Hu; Xiaoyan Liu; Feng Xu; Na Zhang; Huicong Kang
Journal:  Mol Neurobiol       Date:  2017-05-10       Impact factor: 5.590

5.  Chronic treatment with DCPCX, an adenosine A(1) antagonist, worsens long-term memory.

Authors:  Craig Vollert; Gloria S Forkuo; Richard A Bond; Jason L Eriksen
Journal:  Neurosci Lett       Date:  2013-06-06       Impact factor: 3.046

Review 6.  Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review.

Authors:  F Panza; V Solfrizzi; M R Barulli; C Bonfiglio; V Guerra; A Osella; D Seripa; C Sabbà; A Pilotto; G Logroscino
Journal:  J Nutr Health Aging       Date:  2015-03       Impact factor: 4.075

7.  Working memory and the homeostatic control of brain adenosine by adenosine kinase.

Authors:  P Singer; S McGarrity; H-Y Shen; D Boison; B K Yee
Journal:  Neuroscience       Date:  2012-04-19       Impact factor: 3.590

8.  Hyperalgesia, low-anxiety, and impairment of avoidance learning in neonatal caffeine-treated rats.

Authors:  Hong-Zhen Pan; Hwei-Hsien Chen
Journal:  Psychopharmacology (Berl)       Date:  2006-11-10       Impact factor: 4.530

9.  The role of adenosine in Alzheimer's disease.

Authors:  Anisur Rahman
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

10.  Isoflurane anesthesia in aged mice and effects of A1 adenosine receptors on cognitive impairment.

Authors:  Chun-Long Zuo; Chun-Man Wang; Jin Liu; Ting Shen; Jiang-Ping Zhou; Xin-Rui Hao; Yi-Zhao Pan; Hua-Cheng Liu; Qing-Quan Lian; Han Lin
Journal:  CNS Neurosci Ther       Date:  2018-01-17       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.